UNSPSC 51263501: Hexoprenaline

This classification denotes an adrenergic beta-2 receptor agonist, bronchodilator agent, and tocolytic agent with the molecular formula C22H32N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G9L6B3W684, chemically known as 1,12-bis(3,4-dihydroxyphenyl)-3,10-diaza-1,12-dodecandiol but generally known as hexoprenaline, which bears US NIH Compound Identifier 3609. European Medicines Agency schedules Hexoprenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08041MIG.

UNSPSC 51263501 Hexoprenaline, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The one directly relevant recent opportunity — Seminole County, Florida's IFB for naloxone and drug deactivation systems posted June 30, 2026, with a July 26, 2023 response deadline — demonstrates that state and local jurisdictions do procure emergency pharmaceutical products and related systems through competitive sealed bid processes. However, a second recent opportunity tagged to this code, the Texas Health and Human Services Commission's RFI on therapeutic pharmacy initiative direct-to-manufacturer prescriptions (posted April 3, 2026), addresses pharmacy benefit program contracting strategy rather than procurement of hexoprenaline or related emergency pharmaceuticals, suggesting either misclassification or significant scope drift in how state and local bodies are tagging opportunities under this code.

The issuing-body mix in recent activity is limited to health-focused state and local agencies — Seminole County's community health program and the Texas HHS Commission. The Seminole County solicitation represents a straightforward consumables procurement (1,900 units of naloxone and 800 safe drug deactivation systems annually) with quarterly deliveries, E-Verify compliance requirements, a two-year initial term with one-year renewal option, and potential FEMA funding. Geographic activity appears concentrated in Florida and Texas. The sparse recent activity under this code suggests either low demand for hexoprenaline specifically among state and local buyers, inconsistent application of this commodity code to pharmaceutical procurements, or both. Business development professionals should verify whether opportunities labeled under this code align with their product scope before pursuing.